Gregory MSClinical trial: An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
Clinical trial: Clinical Study on the Safety, Efficacy, and Pharmacokinetics of Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Neurological Autoimmune Diseases
Clinical trial: A Phase 4, Interventional, Multicenter, Open-Label, Single-Arm Study to Assess Behavioral and Other Co-occurring Outcomes Following Treatment With EPID(I/Y)OLEX as Add-on Therapy in Participants (Aged 1 to 65 Years Old) With Seizures Associated With Tuberous Sclerosis Complex
Clinical trial: Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)
Shawn Wildermuth (🇺🇦++)Stories I like:
Navigating State Management in Vue: Composables, Provide/Inject, and Pinia - Michael Hoffmann
https://mokkapps.de/blog/vue-state-management-composables-provide-inject-pinia
LPX-TI641 is an orally bioavailable, clinical-stage small-molecule agonist of Tim-3/4. It promotes antigen-independent immune tolerance through Tim receptor agonism and Treg expansion. In EAE models, treatment significantly reduced disease severity, prevented relapses, and maintained clinical benefit after discontinuation.
Oxyxymatrine is an alkaloid with the property of immunomodulation. It inhibits experimental autoimmune encephalomyelitis (EAE) by promoting the production of interferon-β (IFN-β). It also reduces microglia/macrophage infiltration and polarization, lowered pro-inflammatory cytokine levels, and enhanced expression of IL-10 and IL-27. It upregulated the STING/TBK1/IR
Zykino
Poliumoside (POL) is an anti-inflammatory, antioxidant, and neuroprotective molecule. Spinal cord injury (SCI) is a debilitating neurological disorder. Systemic drug toxicity for two POL dosages (15 mg/kg, 30 mg/ kg) was evaluated across multiple organs. Pol-treated mice exhibited pronounced locomotor function enhancement, diminished neuronal tissue depletion, elevated neuronal surviv...
Dimethyl fumarate (DMF) is an oral therapy approved for the treatment of relapsing-remitting multiple sclerosis. It is also known to reduce disease severity in experimental autoimmune encephalomyelitis (EAE). Female C57BL/6J mice were immunized with MOG35-55 to induce EAE and treated with DMF (7.5 mg/kg, oral gavage, every 12 h) or vehicle starting at